Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
Identifieur interne : 002D84 ( Main/Exploration ); précédent : 002D83; suivant : 002D85Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
Auteurs : RBID : pubmed:16183526English descriptors
- KwdEn :
- Gastrointestinal Neoplasms (diagnosis), Gastrointestinal Neoplasms (metabolism), Gastrointestinal Neoplasms (therapy), Humans, Indium Radioisotopes (diagnostic use), MAP Kinase Kinase 2 (physiology), Neovascularization, Physiologic (physiology), Pancreatic Neoplasms (diagnosis), Pancreatic Neoplasms (metabolism), Pancreatic Neoplasms (therapy), Receptors, Somatostatin (physiology), Signal Transduction (physiology), Somatostatin (analogs & derivatives), Somatostatin (diagnostic use), Vascular Endothelial Growth Factor A (physiology).
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Indium Radioisotopes, Somatostatin.
- diagnosis : Gastrointestinal Neoplasms, Pancreatic Neoplasms.
- metabolism : Gastrointestinal Neoplasms, Pancreatic Neoplasms.
- chemical , physiology : MAP Kinase Kinase 2, Neovascularization, Physiologic, Receptors, Somatostatin, Signal Transduction, Vascular Endothelial Growth Factor A.
- therapy : Gastrointestinal Neoplasms, Pancreatic Neoplasms.
- Humans.
Abstract
Somatostatin is a neuropeptide that acts as an endogenous inhibitor of various cellular functions including endocrine and exocrine secretions and the proliferation of normal and tumour cells. Its action is mediated by a family of G-protein-coupled receptors (sst1-sst5) that are widely distributed in normal and tumour cells. Gastroenteropancreatic endocrine tumours express multiple somatostatin receptors, sst2 being clearly predominant. These receptors represent the molecular basis for the clinical use of somatostatin analogues in the treatment of endocrine tumours and their in vivo localisation. This review covers current knowledge in somatostatin receptor biology and signalling.
DOI: 10.1016/j.bpg.2005.03.007
PubMed: 16183526
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.</title><author><name sortKey="Guillermet Guibert, Julie" uniqKey="Guillermet Guibert J">Julie Guillermet-Guibert</name><affiliation wicri:level="1"><nlm:affiliation>IFR31, Institut Louis Bugnard, BP 84225, INSERM U531, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IFR31, Institut Louis Bugnard, BP 84225, INSERM U531, Toulouse</wicri:regionArea><placeName><region type="région">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lahlou, Hicham" uniqKey="Lahlou H">Hicham Lahlou</name></author><author><name sortKey="Pyronnet, Stephane" uniqKey="Pyronnet S">Stéphane Pyronnet</name></author><author><name sortKey="Bousquet, Corinne" uniqKey="Bousquet C">Corinne Bousquet</name></author><author><name sortKey="Susini, Christiane" uniqKey="Susini C">Christiane Susini</name></author></titleStmt><publicationStmt><date when="2005">2005</date><idno type="doi">10.1016/j.bpg.2005.03.007</idno><idno type="RBID">pubmed:16183526</idno><idno type="pmid">16183526</idno><idno type="wicri:Area/Main/Corpus">002D78</idno><idno type="wicri:Area/Main/Curation">002D78</idno><idno type="wicri:Area/Main/Exploration">002D84</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Gastrointestinal Neoplasms (diagnosis)</term><term>Gastrointestinal Neoplasms (metabolism)</term><term>Gastrointestinal Neoplasms (therapy)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>MAP Kinase Kinase 2 (physiology)</term><term>Neovascularization, Physiologic (physiology)</term><term>Pancreatic Neoplasms (diagnosis)</term><term>Pancreatic Neoplasms (metabolism)</term><term>Pancreatic Neoplasms (therapy)</term><term>Receptors, Somatostatin (physiology)</term><term>Signal Transduction (physiology)</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (diagnostic use)</term><term>Vascular Endothelial Growth Factor A (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Somatostatin</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Gastrointestinal Neoplasms</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Gastrointestinal Neoplasms</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>MAP Kinase Kinase 2</term><term>Neovascularization, Physiologic</term><term>Receptors, Somatostatin</term><term>Signal Transduction</term><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Gastrointestinal Neoplasms</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Somatostatin is a neuropeptide that acts as an endogenous inhibitor of various cellular functions including endocrine and exocrine secretions and the proliferation of normal and tumour cells. Its action is mediated by a family of G-protein-coupled receptors (sst1-sst5) that are widely distributed in normal and tumour cells. Gastroenteropancreatic endocrine tumours express multiple somatostatin receptors, sst2 being clearly predominant. These receptors represent the molecular basis for the clinical use of somatostatin analogues in the treatment of endocrine tumours and their in vivo localisation. This review covers current knowledge in somatostatin receptor biology and signalling.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16183526</PMID><DateCreated><Year>2005</Year><Month>09</Month><Day>26</Day></DateCreated><DateCompleted><Year>2006</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1521-6918</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Best practice & research. Clinical gastroenterology</Title><ISOAbbreviation>Best Pract Res Clin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.</ArticleTitle><Pagination><MedlinePgn>535-51</MedlinePgn></Pagination><Abstract><AbstractText>Somatostatin is a neuropeptide that acts as an endogenous inhibitor of various cellular functions including endocrine and exocrine secretions and the proliferation of normal and tumour cells. Its action is mediated by a family of G-protein-coupled receptors (sst1-sst5) that are widely distributed in normal and tumour cells. Gastroenteropancreatic endocrine tumours express multiple somatostatin receptors, sst2 being clearly predominant. These receptors represent the molecular basis for the clinical use of somatostatin analogues in the treatment of endocrine tumours and their in vivo localisation. This review covers current knowledge in somatostatin receptor biology and signalling.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guillermet-Guibert</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Affiliation>IFR31, Institut Louis Bugnard, BP 84225, INSERM U531, Toulouse, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Lahlou</LastName><ForeName>Hicham</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Pyronnet</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bousquet</LastName><ForeName>Corinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Susini</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Best Pract Res Clin Gastroenterol</MedlineTA><NlmUniqueID>101120605</NlmUniqueID><ISSNLinking>1521-6918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>138661-02-6</RegistryNumber><NameOfSubstance>pentetreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.12.2</RegistryNumber><NameOfSubstance>MAP Kinase Kinase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y">Gastrointestinal Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">MAP Kinase Kinase 2</DescriptorName><QualifierName MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neovascularization, Physiologic</DescriptorName><QualifierName MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Pancreatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>97</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S1521-6918(05)00062-4</ArticleId><ArticleId IdType="doi">10.1016/j.bpg.2005.03.007</ArticleId><ArticleId IdType="pubmed">16183526</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16183526
|texte= Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16183526" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |